Lenvatinib in the treatment of radiofrequency papillary thyroid carcinoma
MUDr. Kateřina Kopečková
Onkologická klinika 2. LF UK a FN v Motole, Praha
Differentiated carcinomas represent 90% of all thyroid malignancies. Median survival in radiofrequency (RAF) carcinomas (10-20% of all tumors) is 2.5-3.5 years. New knowledge in the field of molecular genetics has been the basis for the development of new systemic drug therapies. The multikinase inhibitor lenvatinib is authorized for the treatment of RAF differentiated thyroid carcinoma on the basis of a randomized, placebo-controlled clinical study achieving 18.3 months of progression-free with levantinib versus 3.6 months compared to the placebo. The safety profile is comparable to other tyrosine kinase inhibitors and side effects associated with treatment with lentavinib are manageable. The indication limitation is for the patients not treated with another tyrosine kinase inhibitor in ECOG 0-1 state. In conclusion, we add a personal case report (patient's testimony) with a long-term effect of administering lenvatinib.
thyroid gland, differentiated carcinoma, tyrosine kinase inhibitor, lenvatinib, case report
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...